Substance use has been identified as a notable phenomenon in reception settings in EU Member States and the Schengen associated countries. The EUAA is thus putting prevention in focus when working with applicants and particularly so with boy applicants who are the group identified as most at...

EU Drug Market: MDMA describes the European MDMA market from production to trafficking, distribution and use. It details the materials, processes and players involved at different stages and levels of the market. The module takes a threat assessment approach, identifying key issues and defining...

Sharing used injection equipment is one of the main ways in which drug users run the risk of infection (e.g., with HIV, or hepatitis B and C). This has led to the introduction of harm reduction (HR) strategies, such as needle exchange programmes (NEPs). Injection use is considered to be less...

This page provides an overview of key issues related to the provision of harm reduction equipment for high-risk drug use, including service delivery, guidance and evidence, and considerations for implementation. It also considers implications for policy and practice.

This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social responses to cannabis-related problems, and reviews the...